company background image
IMU logo

Imugene ASX:IMU Stock Report

Last Price

AU$0.058

Market Cap

AU$424.5m

7D

-3.3%

1Y

-39.6%

Updated

14 Jun, 2024

Data

Company Financials +

IMU Stock Overview

A clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.

IMU fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Imugene Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Imugene
Historical stock prices
Current Share PriceAU$0.058
52 Week HighAU$0.15
52 Week LowAU$0.039
Beta3.19
1 Month Change-17.14%
3 Month Change-49.57%
1 Year Change-39.58%
3 Year Change-83.89%
5 Year Change286.67%
Change since IPO-40.51%

Recent News & Updates

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Apr 12
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Recent updates

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Apr 12
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Sep 19
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

May 30
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Jan 30
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11
Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17
A Look At Imugene's (ASX:IMU) CEO Remuneration

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Shareholder Returns

IMUAU BiotechsAU Market
7D-3.3%-0.8%-0.9%
1Y-39.6%4.1%8.6%

Return vs Industry: IMU underperformed the Australian Biotechs industry which returned 4.1% over the past year.

Return vs Market: IMU underperformed the Australian Market which returned 8.6% over the past year.

Price Volatility

Is IMU's price volatile compared to industry and market?
IMU volatility
IMU Average Weekly Movement9.6%
Biotechs Industry Average Movement11.0%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.4%
10% least volatile stocks in AU Market3.2%

Stable Share Price: IMU's share price has been volatile over the past 3 months.

Volatility Over Time: IMU's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1986n/aLeslie Chongwww.imugene.com

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in phase 2 study for gastric cancer.

Imugene Limited Fundamentals Summary

How do Imugene's earnings and revenue compare to its market cap?
IMU fundamental statistics
Market capAU$424.55m
Earnings (TTM)-AU$89.24m
Revenue (TTM)AU$15.03m

28.2x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMU income statement (TTM)
RevenueAU$15.03m
Cost of RevenueAU$0
Gross ProfitAU$15.03m
Other ExpensesAU$104.27m
Earnings-AU$89.24m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.012
Gross Margin100.00%
Net Profit Margin-593.63%
Debt/Equity Ratio0%

How did IMU perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.